SCHEMBL1248959

SCHEMBL1248959

Cc1ccc(NC(=O)c2ccc3nc(-c4c(C)cccc4Cl)[nH]c3c2)cc1C

nearest known ligand 0.86

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.86
CYP3A4 P08684 1/20 0.58
NR2E3 Q9Y5X4 4/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KDR P35968 2/20 0.53
CHEK2 O96017 1/20 0.51
HDAC3 O15379 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
CHEK1 O14757 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250412 0.96 DGAT1 (0.82) DGAT1CYP3A4NR2E3NPC1RAB9A
SCHEMBL1251155 0.93 DGAT1 (1.00) DGAT1CYP3A4NPC1RAB9ASMN1; SMN2
SCHEMBL1250718 0.92 DGAT1 (0.76) DGAT1CYP3A4NR2E3NPC1RAB9A
SCHEMBL1249204 0.90 DGAT1 (0.77) DGAT1CYP3A4NR2E3SMN1; SMN2KDR
SCHEMBL11411628 0.89 DGAT1 (0.68) DGAT1CYP3A4NR2E3NPC1RAB9A
SCHEMBL1248653 0.87 DGAT1 (0.76) DGAT1CYP3A4NR2E3KDRCHEK2
SCHEMBL11408545 0.86 DGAT1 (0.64) DGAT1CYP3A4NR2E3KDRCHEK2
SCHEMBL1251539 0.85 DGAT1 (0.84) DGAT1CYP3A4NR2E3KDRCHEK2
SCHEMBL1248735 0.85 DGAT1 (0.69) DGAT1CYP3A4NR2E3KDRCHEK2
SCHEMBL1250402 0.85 DGAT1 (0.75) DGAT1CYP3A4NR2E3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 DGAT1 1/4885CYP3A4 2887/4885NR2E3 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.